The Depixus Research Program is now open: Bring the power of magnetic force spectroscopy to your research for free
23rd July 2024
The Depixus Research Program is a unique opportunity to explore the potential of single molecule interactomics in your research and see biology as it really happens.
Read More
Using MAGNA™ to explore drugs targeting RNA riboswitches
06th March 2024
We’ve been working with Dr Jay Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA™ technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.
Read More
Depixus wins SLAS2024 Ignite Award for MAGNA™ technology
12th February 2024
Paris, France – Depixus CEO Gordon Hamilton Receives The SLAS2024 Ignite Award From Judge Severine Tamas-Lhoustau, CEO Of Novoptim.
Read More
Depixus appoints as Chief Commercial Officer to drive the commercialization of its groundbreaking MAGNA™ technology
11th January 2024
PARIS, France – Interactomics pioneer Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer from January 16, 2024. Klose will lead the company’s commercial growth strategy to build a highly effective sales and support organization, strengthening its market presence ahead of the commercial launch of its first laboratory instrument, MAGNA One™, in 2024.
Read More
Depixus launches technology access program with first MAGNA One™ instrument placement
4th January 2024
PARIS, France – Interactomics pioneer Depixus has launched its game-changing MAGNA technology access program with the deployment of the first ‘MAGNA One’ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at the École Normale Supérieure (ENS), Paris.
Read More
Depixus announces strategic collaboration with Daiichi Sankyo to use MAGNA™ technology to accelerate RNA-targeted drug discovery
12th December 2023
PARIS, France– Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted drug discovery…
Read More
Depixus selected for SLAS 2024 Innovation AveNEW Award
1st November 2023
PARIS, FRANCE – Interactomics pioneer Depixus is proud to announce they have been selected for the prestigious Innovation AveNEW showcase at the Society for Laboratory Automation and Screening (SLAS) International Conference & Exhibition, to be held in Boston from 3rd-7th February 2024. Designed to highlight exciting companies providing game-changing technologies for the life sciences, the …
Read More
Depixus to showcase unique single molecule technology solving the hit-to-lead challenge in RNA-targeted drug discovery at upcoming Discovery on Target Conference
20th September 2023
PARIS–(BUSINESS WIRE)–Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA…
Read More